Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Osteoporosis, Prostate Cancer
Interventions: calcium carbonate, cholecalciferol, Estrogen Antagonists, risedronate sodium, placebo; Dietary Supplement · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 112
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 71 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Testosterone Cypionate, Sipuleucel-T; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Malnutrition
Interventions: Kabiven®, Compounded standard parenteral nutrition; Drug
Lead sponsor: Fresenius Kabi; Industry
Eligibility: 2 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Chicago, Illinois • Kansas City, Missouri

Conditions: Mature Cataracts
Interventions: DYME; Drug
Lead sponsor: Aqumen Biopharmaceuticals, N.A.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Fayetteville, Arkansas • Inglewood, California • Sacramento, California + 13 more

Conditions: Prostate Cancer
Interventions: Curcumin, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 40 Years to 89 Years · Male only
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections
Interventions: Maraviroc; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 3
States / cities: Los Angeles, California • San Diego, California • Torrance, California

Conditions: Healthy
Interventions: Fenofibric Acid 105 mg Tablet; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Cervical Radiculopathy
Interventions: cervical interlaminar with lidocaine, cervical interlaminar with normal saline, Lidocaine, Triamcinolone Acetonide, Normal saline; Procedure · Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Obesity or Overweight
Interventions: AZD9550, AZD6234, Placebo comparator; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 29
States / cities: Dothan, Alabama • Vestavia Hills, Alabama • Cerritos, California + 26 more

Conditions: Colorectal Cancer
Interventions: FOLFOX (chemotherapy), 5 FUCMT (chemoradiation), surgery, magnetic resonance imaging or endorectal ultrasound; Drug · Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1048
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 613 more

Conditions: Metastatic Breast Cancer
Interventions: Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan, Abemaciclib, Fulvestrant, Ribociclib (Dose #1), Inavolisib (Dose #1), Trastuzumab Deruxtecan, Ribociclib (Dose #2), Letrozole, Inavolisib (Dose #2), Empagliflozin, Palbociclib, Metformin, Atirmociclib, Giredestrant; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 26
States / cities: Duarte, California • Irvine, California • La Jolla, California + 20 more

Conditions: Myeloid Diseases
Interventions: DFV890; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 11
States / cities: Stanford, California • Tampa, Florida • Chicago, Illinois + 7 more

Conditions: Marijuana Impairment, Alcohol Impairment
Interventions: Low Marijuana, Hash, THC, or Grass, High Marijuana, Hash, THC, or Grass, Placebo, 0.05 BAC Alcohol, 0.08 BAC Alcohol; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 40 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Plaque Psoriasis
Interventions: ORKA-001; Drug
Lead sponsor: Oruka Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 26
States / cities: Phoenix, Arizona • North Little Rock, Arkansas • Fountain Valley, California + 20 more

Conditions: Ulcerative Colitis
Interventions: Interleukin-2 (aldesleukin).; Drug
Lead sponsor: Scott B. Snapper, MD PHD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Non-small Cell Lung Carcinoma
Interventions: Trastuzumab deruxtecan (DS-8201a), Pembrolizumab; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: San Francisco, California • New Haven, Connecticut • Jacksonville, Florida + 6 more

Conditions: Kidney Transplant Recipient
Interventions: Abatacept 125Mg/Ml Syringe; Drug
Lead sponsor: Idelberto Badell; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Covid19
Interventions: Colchicine 0.6 mg, Naltrexone; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Saint Louis Park, Minnesota • Saint Paul, Minnesota

Conditions: Asthma
Interventions: fluticasone, Standard Asthma Discharge Instructions; Drug · Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 3 Years to 12 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Chronic Stable Angina Pectoris
Interventions: T89 capsule, Placebo capsule; Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 765 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Naples, Florida

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Gemcitabine, ACR-368; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Generalized Anxiety Disorder
Interventions: CYB004, Psychotherapy; Drug · Behavioral
Lead sponsor: Cybin IRL Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Hollywood, Florida • Miami Lakes, Florida • Atlanta, Georgia + 3 more

Conditions: Chronic Low Back Pain, Negative Affectivity
Interventions: Antidepressant, Enhanced Fear Avoidance Rehabilitation; Drug · Other
Lead sponsor: Ajay Wasan, MD, Msc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Chestnut Hill, Massachusetts • Rochester, Minnesota • Pittsburgh, Pennsylvania

Conditions: Reduction of Small Intestinal Ulceration Risk
Interventions: Bif195, Placebo; Dietary Supplement
Lead sponsor: Chr Hansen; Industry
Eligibility: 40 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age

DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery

Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance

CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery

Four Arm Food Effect Study of Fenofibric Acid Tablets

Does Low-does Cervical Epidural Lidocaine Cause Transient Weakness?

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

Examine the Feasibility of a Standardized Field Test for Marijuana and Alcohol Impairment: Laboratory Evaluations

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Low Dose IL-2 for Ulcerative Colitis

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Subcutaneous Abatacept in Renal Transplant Recipients

Impact of Colchicine and Low-dose Naltrexone on COVID-19

Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma

Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)

Treating Negative Affect in Low Back Pain Patients

The Effect of a Probiotic Strain on Aspirin-induced GI Damage